GSK applications for sinus disease treatment accepted for review

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and ...

Alliance News 28 January, 2025 | 9:10AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and the EU.

The London-based pharmaceutical and biotechnology firm said it submitted new drug applications to the China National Medical Products Administration and the Japanese Ministry of Health, Labour & Welfare, alongside its submission of a marketing authorisation application for the drug to the European Medicines Agency.

The applications were for the use of depemokimab in adult and adolescent patients with asthma with type 2 inflammation, and as an add-on treatment for adult patients with inadequately controlled CRSwNP.

CRSwNP is a chronic inflammatory sinus disease, with 80% of patients showing evidence of the type 2 airway inflammation associated with more severe diseases and symptoms.

Depemokimab is not currently approved anywhere as a treatment, though its extended half-life, high potency and high-binding affinity for IL-5 means it could potentially provide sustained inhibition of inflammatory functions in patients, with dosing once every six months.

GSK Global Head of Respiratory/Immunology Reseearch & Development Kaivan Khavandi said: "Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for patients and health systems.

"Our Swift and Anchor trials support depemokimab's potential to suppress IL-5, a known driver of type 2 inflammation, to offer patients sustained inhibition of a key driver of their disease with just two doses per year."

Shares in GSK were up 0.1% at 1,404.00 pence each in London on Tuesday morning.

By Emily Parsons, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GSK PLC 1,400.50 GBX 0.94

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures